CohBar Inc. � CB4211 (NASH)

CohBar Inc. is a biotechnology company focused on the research and development of mitochondria-based therapeutics (MBTs) to treat age-related diseases and extend healthy lifespan. The company works on discovering and developing novel peptides encoded within the mitochondrial genome, which have the potential to regulate various biological processes and address a wide range of age-related conditions such as obesity, type 2 diabetes, cancer, and cardiovascular and neurodegenerative diseases.,CB4211 recently completed phase one testing for non-alcoholic steatohepatitis . Joseph J. Sarret MD, JD, is the current CEO.